drugset / Trial / NCT00468975

A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.

NCT00468975

Phase 2 Completed 42 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

A study to determine the ability of different doses of PF-610,355 to open the airways in asthmatic patients by comparison with placebo and a marketed drug that also opens the airways in asthmatic patients.

Timeline

Start
2007-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-00610355 Small molecule
Subject Salmeterol Other / unclassified

Indications